Weight-Loss Outcomes: A Systematic Review and Meta-Analysis of Weight-Loss Clinical Trials with a Minimum 1-Year Follow-Up

Minneapolis Heart Institute, Minneapolis, Minnesota, United States
Journal of the American Dietetic Association (Impact Factor: 3.92). 11/2007; 107(10):1755-67. DOI: 10.1016/j.jada.2007.07.017
Source: PubMed

ABSTRACT To assist health professionals who counsel patients with overweight and obesity, a systematic review was undertaken to determine types of weight-loss interventions that contribute to successful outcomes and to define expected weight-loss outcomes from such interventions.
A search was conducted for weight-loss-focused randomized clinical trials with >or=1-year follow-up. Eighty studies were identified and are included in the evidence table.
The primary outcomes were a measure of weight loss at 6, 12, 24, 36, and 48 months. Eight types of weight-loss interventions-diet alone, diet and exercise, exercise alone, meal replacements, very-low-energy diets, weight-loss medications (orlistat and sibutramine), and advice alone-were identified. By using simple pooling across studies, subjects mean amount of weight loss at each time point for each intervention was determined.
Efficacy outcomes were calculated by meta-analysis and provide support for the pooled data. Hedges' gu was combined across studies to obtain an average effect size (and confidence level).
A mean weight loss of 5 to 8.5 kg (5% to 9%) was observed during the first 6 months from interventions involving a reduced-energy diet and/or weight-loss medications with weight plateaus at approximately 6 months. In studies extending to 48 months, a mean 3 to 6 kg (3% to 6%) of weight loss was maintained with none of the groups experiencing weight regain to baseline. In contrast, advice-only and exercise-alone groups experienced minimal weight loss at any time point.
Weight-loss interventions utilizing a reduced-energy diet and exercise are associated with moderate weight loss at 6 months. Although there is some regain of weight, weight loss can be maintained. The addition of weight-loss medications somewhat enhances weight-loss maintenance.

Download full-text


Available from: Nicolaas P Pronk, Sep 01, 2015
  • Source
    • "African-American women have the highest prevalence of obesity compared with any other subgroup, with 56.6% classified as obese, defined as a body mass index (BMI) ≥ 30 kg/m 2 , compared with 32.8% of their white counterparts [1]. In general, behavioral weight loss interventions have been successful in reducing weight among obese adults (e.g., [2] [3] [4]). According to the National Institute of Health clinical guidelines, behavioral weight loss interventions featuring diet (decreased energy intake), physical activity (increased energy expenditure ), and behavioral therapy (behavior modification) components typically result in approximately 5–10% weight loss after 6 months of intervention [2] [5] [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the high prevalence of obesity among African American women and modest success in behavioral weight loss interventions, the development and testing of weight management interventions using a community-based participatory research (CBPR) approach has been limited. Doing Me: Sisters Standing Together for Healthy Mind and Body (Doing Me!) is an intervention adapted from an evidence-based behavioral obesity intervention using a CBPR approach. The purpose of Doing Me! is to test the feasibility and acceptability of this adapted intervention and determine its efficacy in achieving improvements in anthropometrics, diet, and physical activity. Sixty African American women, from a low-income, urban community, aged 30-65 years will be randomized to one of two arms: 16-week Doing Me! (n=30) or waitlist control (n=30). Doing Me! employs CBPR methodology to involve community stakeholders and members during the planning, development, implementation, and evaluation phases of the intervention. There will be thirty-two 90-minute sessions incorporating 45minutes of instruction on diet, physical activity, and/or weight management plus 45minutes of physical activity. Data will be collected at baseline and post-intervention (16weeks). Doing Me! is one of the first CBPR studies to examine the feasibility/acceptability of an adapted evidence-based behavioral weight loss intervention designed for obese African American women. CBPR may be an effective strategy for implementing a weight management intervention among this high-risk population. Copyright © 2015. Published by Elsevier Inc.
    Contemporary clinical trials 06/2015; 43. DOI:10.1016/j.cct.2015.06.006 · 1.99 Impact Factor
  • Source
    • "These trials are largely an academic activity hardly applicable to real-life; patients will relapse once the intervention is over as they, or their physicians cannot sustain the major intervention efforts it requires. Weight loss among participants in diet trials will at best average 3 to 4 kg after 2 to 4 years [58] even less among poor and uneducated people who are hit hardest by obesity [59]. Even more worrisome is that individual treatments are powerless against an obesigenic environment that offers so many high-calorie foods and labor-saving devices [60]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Of all the aspects of non-alcoholic fatty liver disease (NAFLD), the slowest advances have occurred in the therapeutic field. Thirty-five years after its formal description and after 15 years of intense scrutiny from researchers worldwide, there is still no approved drug for the treatment of non-alcoholic steatohepatits (NASH). In the meantime, progress in the understanding of pathophysiology, diagnosis - both invasive and non-invasive, epidemiology and even natural history have been substantial or, at times, spectacular. In contrast, hepatitis C virus (HCV) therapy underwent constant improvement and even before the great acceleration of the past few years, patients were already being offered approved therapies that were increasingly more efficient. What then explains such a slow pace of therapeutic advances in NASH, and will this change in the near future? Here we will review commonly-held myths that have diverted attention from therapy of NASH, obstacles that have slowed down industrial development of drugs for this indication, and recent achievements that will create better conditions for drug development programs. We will also briefly review current knowledge of non-pharmacological and pharmacological management in this early era of NASH therapies. Copyright © 2015. Published by Elsevier B.V.
    Journal of Hepatology 04/2015; 62(1S):S65-S75. DOI:10.1016/j.jhep.2015.02.041 · 10.40 Impact Factor
  • Source
    • "One reason often given for not using formula diet weight loss programmes is that any weight lost will be rapidly regained, and early papers have clearly shown that this can be the case (Franz et al. 2007). Overall, there was a general failure to incorporate education and interventions to achieve successful weight maintenance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The changing pattern of obesity-related disease has created a need for a greater range of weight management options for the increasing number of people for whom weight loss and maintenance cannot be addressed by conventional dietary methods.Formula diet weight loss programmes [very low-calorie diets (VLCDs) (400–800 kcal/day) and low-calorie diets (LCDs) (800–1200 kcal/day)] can deliver weight loss at rates of 1–2 kg/week. This rate of weight loss can result in 10–20 kg weight loss in 8–12 weeks. Many health benefits associated with weight reduction seem to require between 10 and 20 kg weight loss. Formula diet programmes can result in weight loss, reduction of liver volume and reduction of visceral fat before bariatric surgery; weight loss before knee joint replacement surgery has also been shown. The benefit of pre-operative weight loss is still under investigation and such practices before bariatric surgery are variable in surgical units across the UK.Weight loss with formula diet in obesity-associated conditions where inflammation is an important component, such as osteoarthritis and psoriasis, has been demonstrated. Maintenance of about 10% of initial bodyweight loss, with symptom improvement in elderly obese people with knee osteoarthritis, has been shown over a period of 4 years. In obese people with psoriasis, weight loss with skin improvement has been maintained for 1 year.Clinical trials are currently underway to examine the merits of an initial weight loss with formula diet in pre-diabetes, in early type 2 diabetes and in insulin-treated type 2 diabetes.Rapid initial weight loss can result in rapid symptom improvement, such as reduced joint pain in osteoarthritis, improved sleep quality in obstructive sleep apnoea, reduced shortness of breath on exertion, reduced peripheral oedema and rapid improvement in metabolic control in diabetes, all changes that are highly motivating and conducive towards compliance.There is also some evidence for improved vitamin D status and maintained bone health in elderly obese people with osteoarthritis but more research is needed.Rapid initial weight loss was feared to be followed by rapid weight regain. However, provided initial weight loss is delivered in parallel with an intense education programme about nutrition, cooking, shopping and lifestyle for long-term maintenance; and where long-term support is provided, subsequent weight maintenance after VLCDs and LCDs has been shown to be possible. A recent literature review identified high-protein diets, obesity drugs and partial use of formula meal replacements as methods which can result in statistically significantly greater weight maintenance after initial weight loss with VLCDs or LCDs.Anxiety about serious adverse side effects seems to be unfounded although users need to be aware of both minor and more serious, though very infrequent, adverse events, such as gallstones and gallbladder disease.
    Nutrition Bulletin 09/2014; 39(3). DOI:10.1111/nbu.12098
Show more